Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Double-Blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression
Previously Diagnosed and Treated as Recurrent Major Depression: This study recruits males and
females aged 18 - 70 who currently meet diagnostic criteria for bipolar I or bipolar II
disorder and are currently experiencing an episode of major depression. Patients are
randomized to double-blind treatment with divalproex sodium ER or placebo and remain in the
study for up to six weeks. This six-week double-blind treatment period is followed by an
open-label treatment period of six months duration. This study is sponsored by Abbott
Laboratories.